A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting · NCT04830137 · Registry updated 2026-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-03-20 | NCT04830137 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nurix Therapeutics, Inc. | 6 |
16 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.